![Knut Lundin](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Postes actifs de Knut Lundin
Sociétés | Poste | Début | Fin |
---|---|---|---|
ImmusanT, Inc.
![]() ImmusanT, Inc. Medical SpecialtiesHealth Technology ImmusanT, Inc. develops a new class of therapeutic vaccines to change the lives of people living with autoimmune diseases. Its Epitope-Specific Immuno-Therapy platform provides a precision medicine approach to restoring immune tolerance across a range of diseases, including celiac disease and type 1 diabetes. The firm’s product Nexvax2, protects celiac disease patients against the debilitating effects of gluten. The company was by Leslie J. Williams and Robert P. Anderson founded in December 2010 and is headquartered in Cambridge, MA. | Corporate Officer/Principal | - | - |
Historique de carrière de Knut Lundin
Statistiques
Internationale
Etats-Unis | 2 |
Opérationnelle
Corporate Officer/Principal | 1 |
Sectorielle
Health Technology | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
Entreprise privées | 1 |
---|---|
ImmusanT, Inc.
![]() ImmusanT, Inc. Medical SpecialtiesHealth Technology ImmusanT, Inc. develops a new class of therapeutic vaccines to change the lives of people living with autoimmune diseases. Its Epitope-Specific Immuno-Therapy platform provides a precision medicine approach to restoring immune tolerance across a range of diseases, including celiac disease and type 1 diabetes. The firm’s product Nexvax2, protects celiac disease patients against the debilitating effects of gluten. The company was by Leslie J. Williams and Robert P. Anderson founded in December 2010 and is headquartered in Cambridge, MA. | Health Technology |
- Bourse
- Insiders
- Knut Lundin
- Expérience